aTYR PHARMA INC (ATYR) Cash and securities
- Total cash · latest quarter (USD): Value $57.42M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $57.42M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $16.16M + $41.26M ≈ $57.42M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 16.16M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 41.26M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Cash and current securities | 57.42M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $57.42M | (m) | $16.16M | $41.26M | (m) |
| 2026-03-31 | $66.51M | (m) | $10.01M | $56.51M | (m) |
| 2025-12-31 | $78.69M | (m) | $10.74M | $67.94M | (m) |
| 2025-09-30 | $90.20M | (m) | $6.15M | $84.05M | (m) |
| 2025-06-30 | $80.35M | (m) | $17.22M | $63.13M | (m) |
| 2025-03-31 | $76.35M | (m) | $10.36M | $65.99M | (m) |
| 2024-12-31 | $72.13M | (m) | $11.05M | $61.07M | (m) |
| 2024-09-30 | $65.99M | (m) | $11.46M | $54.53M | (m) |
| 2024-06-30 | $78.48M | (m) | $6.80M | $71.68M | (m) |
| 2024-03-31 | $84.50M | (m) | $6.81M | $77.69M | (m) |
| 2023-12-31 | $98.17M | (m) | $22.54M | $75.62M | (m) |
| 2023-09-30 | $102.13M | (m) | $9.79M | $92.34M | (m) |
| 2023-06-30 | $108.58M | (m) | $12.31M | $96.27M | (m) |
| 2023-03-31 | $114.39M | (m) | $20.69M | $93.69M | (m) |
| 2022-12-31 | $66.15M | (m) | $9.98M | $56.16M | (m) |
| 2022-09-30 | $77.37M | (m) | $18.36M | $59.02M | (m) |
| 2022-06-30 | $88.55M | (m) | $8.48M | $80.07M | (m) |
| 2022-03-31 | $98.67M | (m) | $8.32M | $90.34M | (m) |
| 2021-12-31 | $107.91M | (m) | $2.34M | $105.58M | (m) |
| 2021-09-30 | $116.35M | (m) | $59.74M | $56.61M | (m) |
| 2021-06-30 | $44.06M | (m) | $2.19M | $41.87M | (m) |
| 2021-03-31 | $50.64M | (m) | $12.59M | $38.05M | (m) |
| 2020-12-31 | $31.69M | (m) | $16.95M | $14.74M | (m) |
| 2020-09-30 | $36.15M | (m) | $18.15M | $18.00M | (m) |
| 2020-06-30 | $41.43M | (m) | $21.63M | $19.80M | (m) |
| 2020-03-31 | $49.83M | (m) | $39.45M | $10.38M | (m) |
| 2019-12-31 | $31.14M | (m) | $9.21M | $21.93M | (m) |
| 2019-09-30 | $38.06M | (m) | $17.34M | $20.72M | (m) |
| 2019-06-30 | $42.40M | (m) | $14.51M | $27.89M | (m) |
| 2019-03-31 | $43.02M | (m) | $12.96M | $30.05M | (m) |
| 2018-12-31 | $49.55M | (m) | $22.96M | $26.58M | (m) |
| 2018-09-30 | $55.96M | (m) | $31.55M | $24.41M | (m) |
| 2018-06-30 | $64.33M | (m) | $19.27M | $45.06M | (m) |
| 2018-03-31 | $74.10M | (m) | $21.94M | $52.16M | (m) |
| 2017-12-31 | $85.12M | (m) | $21.09M | $64.03M | (m) |
| 2017-09-30 | $90.38M | (m) | $29.77M | $60.62M | (m) |
| 2017-06-30 | $57.22M | (m) | $35.91M | $21.31M | (m) |
| 2017-03-31 | $61.93M | (m) | $28.90M | $33.03M | (m) |
| 2016-12-31 | $72.15M | (m) | $38.39M | $33.76M | (m) |
| 2016-09-30 | $70.53M | (m) | $34.33M | $36.20M | (m) |
| 2016-06-30 | $83.93M | (m) | $43.19M | $40.73M | (m) |
| 2016-03-31 | (m) | (m) | $54.10M | (m) | (m) |
| 2015-12-31 | (m) | (m) | $53.02M | (m) | (m) |
| 2015-09-30 | (m) | (m) | $60.05M | (m) | (m) |
| 2015-06-30 | (m) | (m) | $63.07M | (m) | (m) |
| 2015-03-31 | $54.51M | (m) | $54.51M | $0.00 | (m) |
| 2014-12-31 | $15.85M | (m) | $13.90M | $1.95M | (m) |
| 2014-09-30 | (m) | (m) | $18.73M | (m) | (m) |
| 2014-06-30 | (m) | (m) | $24.64M | (m) | (m) |
| 2014-03-31 | (m) | (m) | $24.52M | (m) | (m) |
| 2013-12-31 | (m) | (m) | $36.46M | (m) | (m) |
| 2012-12-31 | (m) | (m) | $3.67M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |